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The Role and Management of Statins
in Dyslipidemia and Addressing
Patient Barriers to Use

Objectives
• Define the role of statins for patients with diabetes
• Recommend appropriate statin therapy with evidence-based
indications from recent guidelines
• Adjust statin therapy based on barriers encountered with myopathy
and other health concerns
• Describe alternatives to statin therapy

The US Diabetes “Epidemic”
• National prevalence of diabetes (2010)
– Age ≥ 20 years: 11.3% (25.6 million)
– Age ≥ 65 years: 26.9% (10.9 million)
• National prevalence of prediabetes (2010)
– Age ≥ 20 years: 35% (estimated 79 million)
– Age ≥ 65 years: 50%

CDC National Diabetes Fact Sheet 2011

Complications of Diabetes

Macrovascular

Microvascular

Macrovascular Complications
Heart Disease and Stroke
Americans with Diabetes ≥ 35 yo (2011)
• 5 million with heart disease
• 3.7 million with other heart
“condition”
• 2.1 million with reported stroke
• 7.6 million with heart disease or
stroke

http://www.cdc.gov/diabetes/statistics/cvd/fig1.htm

Heart Disease and Stroke
• Diabetes-related death certificates in people ≥ 65 yo (2004)
– Heart disease noted in 68%
– Stroke noted in 16%
• Risk
– Heart disease death rates and risk of stroke are 2 - 4 times higher in
adults with diabetes vs. those without diabetes

CDC National Diabetes Fact Sheet 2011

CHD and Diabetes
• CVD is the major cause of morbidity and mortality in patients with
diabetes
• Dyslipidemia and hypertension are clear risk factors
– Many studies have shown benefit in controlling these to prevent or
slow CVD in diabetes

Buse JB. Diabetes Care 2007
Gaede P. N Engl J Med 2008

Why We Care About Statins

Lipid Guidelines
Review of NCEP ATP III
Highlights of the new 2013 ACC/AHA Blood Cholesterol Guidelines
ADA Guidelines

NCEP ATP III
Released: 2001
Updated: 2004

Goal Values or Targets
• TC
• HDL
• TG

< 200
> 40
< 150

mg/dL
mg/dL (>50mg/dL for women)
mg/dL

• LDL goal must be determined based on risk

NCEP ATP III Expert panel. JAMA 2001; 285(19):2486-97.

NCEP ATP III Guidelines

“LDL is the major atherogenic lipoprotein and has long been identified by NCEP
as the primary target of cholesterol-lowering therapy”
“This focus on LDL has been strongly validated by recent clinical trials, which
show the efficacy of LDL-lowering therapy for reducing risk for CHD”

NCEP ATP III Expert panel. JAMA 2001; 285(19):2486-97.

NCEP ATP III Guidelines

NCEP ATP III Expert panel. JAMA 2001; 285(19):2486-97.

Three Categories of Risk that Modify
LDL-Cholesterol Goals
Risk Category

LDL Goal (mg/dL)

CHD and CHD risk
equivalents

<100

Multiple (2+) risk factors

<130

Zero to one risk factor

<160

NCEP ATP III Expert panel. JAMA 2001; 285(19):2486-97.

LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle
Changes (TLC) and Drug Therapy in Different Risk Categories

Risk Category
CHD or CHD Risk
Equivalents
(10-year risk >20%)

LDL Goal
(mg/dL)
<100
(optional <70)

LDL Level at Which to
Initiate Therapeutic
Lifestyle Changes (TLC)
(mg/dL)
≥100

LDL Level at Which
to Consider
Drug Therapy
(mg/dL)
≥100
(<100: consider drug options)

10-year risk 10–20%:
≥130
2+ Risk Factors
(10-year risk ≤20%)

<130

≥130

(100-129: consider drug
options)

10-year risk <10%: ≥160

0–1 Risk Factor

<160

≥160

NCEP ATP III Expert panel. JAMA 2001; 285(19):2486-97. Grundy SM. Circulation. 110:227-39;2004

≥190
(160-189: LDL-lowering drug
optional)

Optional LDL Goal < 70 mg/dL
• Option for patients at “very high risk”
– Must have established CVD plus any of:
• Multiple major risk factors (especially diabetes)
• Severe and poorly controlled risk factors (especially cigarette
smoking)
• Multiple risk factors of Metabolic Syndrome
– High TG > 200 mg/dL plus
– Non-HDL ≥ 130 mg/dL with low HDL < 40 mg/dL
• History of acute coronary syndromes (ACS)

Grundy SM. Circulation. 110:227-39;2004

Not Good Enough?
• “Half of all myocardial infarctions and strokes occur despite
apparently healthy men and women with LDL levels below
currently recommended thresholds for treatment”
• “Even with adequate LDL lowering, many patients on statin
therapy have significant CVD risk”

Ridker PM. Lancet. 2009; 373:1175-82.
Brunzell JD. Diabetes Care. 2008; 31:811-22

2013 ACC/AHA Guideline on the
Treatment of Blood Cholesterol to
Reduce Atherosclerotic
Cardiovascular Risk in Adults
Released Mid-November 2013
Journal of the American College of Cardiology

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of Cardiology.
2013:doi:10.1016/j.jacc.2013.11.002.

2013 ACC/AHA Blood Cholesterol
Guidelines
• Expert panel for ATP 4
• Partnered with ACC/AHA
• Focus on ASCVD risk reduction, not comprehensive lipid
management
• Only used RCT, systematic reviews, meta-analyses of RCT

3 Critical Questions
1.
2.
3.

What is the evidence for LDL and non-HDL goals for the
secondary prevention of ASCVD?
Same as #1, but primary prevention
For primary and secondary prevention, what is the impact on
lipid levels, effectiveness, and safety of specific cholesterolmodifying drugs used for lipid management in general and in
selected subgroups?

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Findings
• “unable to find evidence to support titrating statins to a target LDL
or non-HDL goal”
• “extensive evidence that appropriate statin intensity should be
used to reduce ASCVD risk”
• “use of non-statins to additionally lower non-HDL once LDL goal
achieved, DID NOT further reduce ASCVD outcomes”

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Findings
• Non-statin therapies in general have not demonstrated significant
ASCVD event reduction.
• Lifestyle modifications remain a critical component of health
promotion and ASCVD risk reduction
• Identification of 4 statin benefit groups to focus on ASCVD risk
reduction

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

4 Statin Benefit Groups
• Clinical ASCVD ≤ 75 yo (secondary prevention)
• Primary elevation of LDL ≥ 190 mg/dL
• 40-75 yo with Diabetes and LDL 70-189 mg/dL
• No clinical ASCVD or Diabetes, 40-75 yo and LDL 70-189 mg/dL and
10-year ASCVD risk of 7.5% or higher

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Stone. 2013 ACC/AHA Blood
Cholesterol Guideline. Journal of
the American College of
Cardiology.
2013:doi:10.1016/j.jacc.2013.11.0
02.

Clinical ASCVD ≤ 75 years
• High-intensity statin therapy (1st line)
• If not tolerated, use moderate-intensity
• If > 75 years, consider benefits vs risks and may use moderateor high-intensity statin

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of
Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

LDL ≥ 190 mg/dL
• High-intensity statin therapy
• If not tolerated, use maximum tolerated intensity
• Once maximum intensity achieved, may consider addition of nonstatins to further lower LDL (weak data—expert opinion)

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of
Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

40-75 years with Diabetes and LDL
70-189 mg/dL
• Moderate-intensity statin therapy
• If ASCVD 10-year risk ≥ 7.5%, use high-intensity
• If < 40 or > 75 years, consider benefits vs risks and patient
preferences

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of
Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

No Clinical ASCVD or Diabetes, 40-75
yo and LDL 70-189 mg/dL and 10-year
ASCVD Risk of 7.5% or Higher
• Moderate- to High-intensity statin therapy

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Adults with LDL <190 mg/dL not
Fitting into a Statin Benefit Group
• Additional factors may be considered to inform treatment decision
making
– LDL ≥ 160 mg/dL
– Genetic hyperlipidemia
– Family history of premature ASCVD ♂< 55 years or ♀< 65 years
– High C-reactive Protein (CRP) > 2 mg/L
– Coronary artery calcium score ≥ 300 Agatston units or ≥ 75
percentile for age, sex, ethnicity
– ABI <0.9
– Lifetime risk of ASCVD
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Intensity of Statin Therapy
• Expected LDL-lowering:
– High-intensity
– Moderate-intensity
– Low-intensity

≥ 50%
30 to < 50%
< 30%

• High-intensity reduces ASCVD risk more
• However, moderate- or low-intensity still provides protection, just
not as much as high-intensity

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Statin Intensity Categories
and Drugs
High-intensity
Atorvastatin 40-80 mg
Rosuvastatin 20-40 mg

Moderate-intensity
Atorvastatin 10-20 mg
Rosuvastatin 5-10 mg
Simvastatin 20-40 mg
Pravastatin 40-80 mg
Lovastatin 40 mg
Fluvastatin XL 80 mg
Fluvastatin 40 mg BID
Pitavastatin 2-4 mg

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Low-intensity
Simvastatin 10 mg
Pravastatin 10-20 mg
Lovastatin 20 mg
Fluvastatin 20-40 mg
Pitavastatin 1 mg

Case Question 1
Patient is a 58 YO male with diabetes and an LDL of 198 mg/dL.
Per the 2013 ACC/AHA guidelines, how should he be treated?
A.
B.
C.
D.

Pravastatin 80 mg
Rosuvastatin 20 mg
Atorvastatin 20 mg
Fluvastatin 40 mg

Case Question 2
Patient is a 62 YO female with diabetes, an LDL of 82 (on no
statin), and an ASCVD 10-year risk of 7.8%. Per 2013 ACC/AHA
guidelines, how should she be treated?
A.
B.
C.
D.

Atorvastatin 80 mg
Pitavastatin 1 mg
Lovastatin 20 mg
Pravastatin 80 mg

Calculation of ASCVD 10-year Risk (%)
• Pooled Cohorts Equations
– Calculates risk of CHD death, fatal or non-fatal MI or stroke
– Used for “white and black men and women” without clinical
ASCVD
– Controversial calculation
• This places many more people in higher risk categories than
the Framingham Risk tool

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Statin Safety Recommendations
• Moderate-intensity statin should be used instead of high-intensity
if high risk of statin-associated adverse effects
– Impaired renal or hepatic function
– Previous stain intolerances or muscle disorder
– ALT > 3 times upper limit of normal (CI)
– On drugs that affect statin metabolism
– > 75 years of age
– Possibly history of hemorrhagic stroke
– Possibly Asian ancestry

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Statin Safety Recommendations
• Monitor creatine kinase (CK or CPK)
– Baseline and if myopathy symptoms
• Monitor ALT (liver function)
– Baseline and if hepatotoxic symptoms
• Consider ↓ statin dose if 2 consecutive LDL < 40 mg/dL
• Avoid simvastatin 80 mg
• Evaluate for new onset diabetes

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Monitoring Statin Therapy
• Initial fasting lipid panel (then start drug)
• Check fasting lipid panel 4-12 weeks (often 6-8 weeks); to check
adherence, NOT to achieve a target or goal
• Then check fasting lipid panel 3-12 months

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Monitoring Statin Therapy
• Insufficient response to statin dose
– Reinforce adherence to medication and lifestyle
– Exclude secondary causes
– If higher-risk ASCVD patients on max statin dose, may consider
adding non-statin
• Clinical ASCVD < 75 years
• Baseline LDL ≥ 190 mg/dL
• 40-75 years old with diabetes

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Summary of Lipid Guideline
Differences
ATP 3

2013 ACC/AHA

• Focus on LDL goals
• Use statins or any lipidlowering drugs to attain goal

• Focus on statin intensity
• Use statins almost exclusively

ADA 2014 Standards of Care
• Statin therapy if LDL > 100 mg/dL
• Statin therapy regardless of baseline lipid levels in DM:
– With overt CVD
– Without CVD, > 40 yoa, ≥ 1 CVD risk factor
• If LDL goal of < 100 mg/dL is not reached with optimal statin dosing,
an LDL reduction of 30 - 40% from baseline is an alternative
therapeutic goal
• “Combination drug therapy has been shown not to provide additional
cardiovascular benefit above statin therapy alone and is not generally
recommended.”

ADA 2014 Standards of Medical Care

ADA 2015 Standards of Care
• High-intensity statin
– All ages with DM and overt CVD
– 40-75 yo DM with additional CVD risk

• Moderate- or High-intensity
statin
– <40 yo DM with additional CVD risk
– >75 yo DM with additional CVD risk

• Moderate-intensity statin
– 40-75 yo DM without additional CVD risk
– >75 yo DM without additional CVD risk

ADA 2015 Standards of Medical Care

• Adjust statin intensity based on
patient response (AE, LDL)
• Lipid panel for monitoring
adherence
• “Combination therapy has not
been shown to provide
additional CVD benefit above
statin therapy alone and is not
generally recommended”

Statin Myopathy

Statin Mechanism of Action

Reduces hepatic cholesterol synthesis, lowering intracellular
cholesterol, which stimulates upregulation of LDL receptors and
increases the uptake of non-HDL particles from the systemic circulation

Definitions of Statin Myopathy
• Myopathy
– Any muscle complaint related to statin use
• Myalgia
– Muscle symptoms without elevated creatine kinase (CK)
• Myositis
– Elevated serum CK with or without muscle symptoms
• Rhabdomyolysis
– Severe muscle symptoms with CK elevated > 10 times the upper
limit of normal (ULN)
Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the
use and safety of statins. Journal of the American College of
Cardiology, 2002.

Characteristics of Statin Myopathy
• Localization: Generalized (60%) or localized to large proximal
muscle groups. Lower extremities more frequently (25%) affected
than upper (8%)
• Type: Heaviness, stiffness, cramps
• “Equivalent” of muscle pain: Weakness, tendonitis
• Frequency and duration: Usually intermittent lasting several
minutes to hours
• Timing: < 1 month to several years

Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the
use and safety of statins. Journal of the American College of
Cardiology, 2002.

Statin Myopathy – Randomized
Controlled Trials (RCT)
• Rarely reported in RCTs
– RCT reported 1-5% of patients experiencing myalgia
– Patients are carefully selected for RCT
• Patients with renal or hepatic insufficiency, poorly controlled
diabetes, history of muscle complaints, and taking drugs with
possible drug interactions usually excluded from trials
– Most studies focus on reporting rhabdo vs. myalgia
– Lack of consensus on definitions

Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the
use and safety of statins. Journal of the American College of
Cardiology, 2002.

Statin Myopathy – Observational
Studies Outpatient
• Higher frequency of myopathy
– 9-20%
• PRIMO Study
– 10.5%

Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the use and safety of statins.
Journal of the American College of Cardiology, 2002. Bruckert E, et al. Mild to moderate
muscular symptoms with dosage statin therapy, PRIMO. Cardiovascular Drugs and
Therapy, 2006.

What Causes Statin Myopathy

Carrier of
SLCO1B1
gene
polymorphisms

Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy.
JAMA. 2003;289:1681–1690). HMG-CoA=3-hydroxy-3methylglutaryl coenzymeA

Drug or food
interactions
(CYP3A4,
CYP2C9, UGT,
OAT1B1)

Pharmacotherapy Considerations
Medication

Lipophilicity

Metabolism

Half-life

Metabolites

Rosuvastatin

Hydrophilic

CYP2C9

~21

Minor active
metabolite

Atorvastatin

Lipophilic

CYP3A4

~15-30

Active metabolite

Simvastatin

Lipophilic

CYP3A4

~2-3

Active metabolite

Pitavastatin

Lipophilic

CYP3A4

~12

No active
metabolite

Lovastatin

Lipophilic

CYP3A4

~3

Active metabolite

Pravastatin

Hydrophilic

Sulfation

~1-3

No active
metabolite

Fluvastatin

Lipophilic

CYP2C9

~5

No active
metabolite

Statin Toxicity
•
•
•
•

Simvastatin 40-80mg – 18.2%
Atorvastatin 40-80mg – 14.9%
Pravastatin 40mg – 10.9%
Fluvastatin XL 80mg – 5.1%

Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the use and safety of statins.
Journal of the American College of Cardiology, 2002. Bruckert E, et al. Mild to moderate
muscular symptoms with dosage statin therapy, PRIMO. Cardiovascular Drugs and
Therapy, 2006.

Risk Factors for Statin Myopathy
Endogenous Risks
• Advanced age (>65)
• Low BMI and frailty
• Multisystem disease
• Hypothyroidism
• Hypertriglyceridemia
• Metabolic muscle disease
• Family history of muscular
symptoms
• History of elevated CK or
muscle symptoms

Exogenous Risks
• Alcohol consumption
• Heavy exercise
• Surgery with severe
metabolic demands
• >1 L grapefruit juice daily
• Drug interactions

Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the use and safety of statins. Journal of the American College of
Cardiology, 2002. Chatzizisis YS, et al. Risk factors and drug interactions predisposing to statin-induced myopathy. Drug Safety, 2010.

Drugs Affecting CYP450 (3A4)
• Cyclosporine
• Nondihydropyridine Calcium Channel Blockers (i.e. verapamil,
diltiazem)
• Amiodarone
• Azole antifungals (i.e. fluconazole)
• Colchicine
• Digoxin
• Protease inhibitors
• Warfarin
• Macrolide antibiotics (i.e. azithromycin)
Lexi-Comp.

Drugs Affecting CYP450 (2C9)
•
•
•
•
•
•
•
•

Azole antifungals (i.e. fluconazole)
H2 receptor antagonists (i.e. ranitidine)
Proton pump inhibitors (i.e. omeprazole)
Warfarin
NSAIDs
Sulfonylureas (i.e. glipizide)
ARBs
Amiodarone

Lexi-Comp.

Gemfibrozil
• Inhibits glucuronidation of UGT
• Inhibits the OATP1B1 transporter
– Increased levels of statin and increased risk of adverse effects

Lexi-Comp. UGT: uridine diphosphate-glucuronosyl transferases

Simvastatin
• SEARCH trial – 80mg vs. 20mg
– Major CV events 24.5% vs. 25.7%
– Myopathy (CK>10x ULN + symptoms)
• 52 patients on 80mg; 1 patient on 20mg
– Rhabdomyolysis (CK>40x ULN + symptoms)
• 22 patients on 80mg; 0 patients on 20mg
– Risk declines from 5 to 2/1000 person years in the first 12
months, then from 1 to 0.4/1000 per years after 12 months
– Risk of myopathy found to be 3x higher and risk of fatal
rhabdomyolysis higher than with more potent LDL lowering drugs
atorvastatin and rosuvastatin
Lancet. 2010;376:1658-69.

Simvastatin Dosing Restrictions
• 80mg restricted to those taking it >12 months prior to 6/8/2011
• Maximum dose of simvastatin established when used concomitantly
with other drugs:
Drug

Simvastatin Max Dose

Amiodarone 20mg

Lexi-Comp.

Amlodipine

20mg

Diltiazem

10mg

Verapamil

10mg

Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy.
JAMA. 2003;289:1681–1690). HMG-CoA=3-hydroxy-3methylglutaryl coenzymeA

CoEnzyme Q10 Supplementation
• Bookstaver and colleagues
– CoQ10 60mg twice daily
– No more effective than placebo in decreasing muscle pain that
was presumed to be statin induced
• Kelly and colleagues
– CoQ10 100mg/day
– Myopathic pain improved from baseline in treated patients
• Ganesan and colleagues
– Relationship of GLUT4 protein levels, CoQ10, and statins

Bookstaver D. Am J Cardiol 2012;110:526-29. Marcoff L. J Am Coll Cardiol. 2007;49:2231-7.
Ganesan S. Metab Syndr Relat Disord 2013. Kelly P. J Am Coll Cardio 2005;45.

CoEnzyme Q10
• Dose: 100-300mg/day in divided doses
• Adverse Effects: (<1%) nausea/vomiting, diarrhea, elevated
transaminases (rare)
• Drug Interactions: diminished effect of warfarin
• Rated as ‘Likely Safe’

Natural Medicines Comprehensive Database

Management of Myopathy
• Muscle symptoms
– Stop statin (2-6 week drug holiday)
– Measure CK, serum creatinine and urinalysis
• Symptoms resolve
– Restart original statin at same or lower dose
– If recurrence, stop original statin
– When symptoms resolve, start new statin at a lower dose
• If not resolved > 2 months, likely not statin; resume original dose
• If intolerant of statins, may use non-statin

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Alternate Statin Dosing
• Use a lower toxicity statin
– Fluvastatin XL 80mg (39% LDL lowering potential)
• Use a statin with less CYP450 dependence
– Pravastatin
• Use alternate day or once/twice weekly dosing with longer acting
statins (rosuvastatin, atorvastatin, pitavastatin)
– 35% LDL lowering with rosuvastatin 5mg every other day
– 26% LDL lowering with rosuvastatin 5-10mg twice weekly

Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Statin Discontinuation
•
•
•
•

Retrospective cohort study: 107,835 patients over 9 years
Statin discontinued: 57,292 (53%)
Statin-related events: 18,778 (17.4%)
Findings:
– Of 11,124 who discontinued, 6579 were re-challenged with statin
over next 12 months
– 92.2% were still taking statin after 12 months
– 2721 who were re-challenged with same statin, 1295 were still
taking 12 months later

Zhang H et al. Ann Intern Med. 2013;158:526-534.

Bottom Line
• Most patient re-challenged can tolerate statins long-term
– Statin-related events may have other causes, are tolerable or may
be specific to individual statins rather than the entire drug class
• If patients develop muscle symptoms after start
– Determine likelihood that muscle symptoms are due to the statin
– Balance of expected statin therapy with the likelihood that muscle
symptoms are due to statin

Zhang H et al. Ann Intern Med. 2013;158:526-534.

Case Question 3
•

45 YO Male with past medical history: hypertension, type 2 diabetes, obesity and
smoker complaining of muscle pain
• Labs: ALT/AST WNL and CK 350
• ASCVD risk is 9%
• Medications: Metformin 500 mg 1 tablet twice daily, Lisinopril 40mg daily, HCTZ 25mg
daily, amlodipine 10mg, and simvastatin 40mg once daily
(History of being started on atorvastatin 80mg once daily but complained of
muscle pain shortly after. PCP immediately switched to simvastatin 40mg.)
Which of the following is the best recommendation:
A.
B.
C.
D.

Change statin therapy to bile acid sequestrant
Decrease simvastatin to 20mg once daily
Provide a 6-week statin drug holiday and re-challenge with atorvastatin 40mg
Discontinue simvastatin and start rosuvastatin 20mg

Other Statin Concerns

Statin and Diabetes
• JUPITER
– N=17,802
– 27% increase in risk of diabetes (p=0.01)
– 39% reduction in primary endpoint (MI, stroke, CV deaths) for
patients with diabetes risk factors and 52% reduction in those
that with no risk factors
– 134 vascular deaths avoided for every 54 new cases of diabetes
• Meta-analysis (PROVE IT-TIMI 22, TNT, IDEAL, A to Z, SEARCH)
– High-dose statins (atorvastatin and simvastatin) increased risk of
diabetes (OR 1.12)
PROVE-IT TIMI 22. Circulation 2004; Sattar N. Lancet 2010;375:735-42; Preiss
D. JAMA 2011;305:2556; Rajpathak SN. Diabetes Care 2009;32:1924.

Statins and Cognitive Impairment /
Dementia
• Meta-analysis evaluating 16 studies: Without baseline cognitive
dysfunction, no effect on cognition
– Long-term data may support beneficial role for statins in
prevention of dementia (HR 0.71, CI 0.61-0.82)
– 5 studies showed 29% reduction in incidence of dementia
• Prospective study of 6,600 patients: Patients with normal
cognitive function or mild cognitive impairment and statin use
performed better on attention measures and had slower annual
worsening of Clinical Dementia Rating Sum of Boxes (P<0.006)
– No difference in cognitive decline
Steenland K. Journal of American Geriatric Society 2013.
61(9):1449-55; Swiger KJ. Mayo Clinic Proceedings 2013

Statins and Acute Kidney Injury
• Retrospective analysis of > 2 million patients on moderate to high
intensity statins:
– Rosuvastatin ≥ 10mg
– Atorvastatin ≥ 20mg
– Simvastatin ≥ 40mg
• 34% greater risk of hospitalization for acute kidney injury (AKI) in
first 120 days of treatment with statin (CI 1.25-1.43)
– NNH was 1700 for 1 AKI hospitalization within the 120 days
• Retrospective analysis of > 3 million patients on statin, no increase
in AKI as a whole
– simvastatin 40-80mg have increased risk of AKI
Dormuth CR. BMJ 2013;346:f880; Layton JB.
Pharmacoepidemiology and Drug Safety 2013;22:1061

Bottom Line
• Diabetes: cardiovascular benefits outweigh the small absolute risks
of developing diabetes
• Dementia: there is no increased risk of cognitive decline, and there
may even be a protective role
• Acute Kidney Injury: cardiovascular benefits of statin therapy
outweigh the proposed risk of acute kidney injury

Dormuth CR. BMJ 2013;346:f880; Layton JB.
Pharmacoepidemiology and Drug Safety 2013;22:1061

Drug Therapy Options

Statin Considerations
Adverse Effects
• Myopathy (rhabdomyolysis)
• Elevated liver transaminases (rare)
Contraindications
• Pregnancy, active liver disease
Monitor
• Fasting lipid profile (6 - 8 weeks)
• Baseline CPK (CK) and again if muscle pain
• Baseline LFT and again periodically

Lexi-Comp. NCEP ATP III Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal
of the American College of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Statin Pearls
• Dose in evening unless long half-life (atorva-, rosuva-)
• Myopathy - rechallenge with lower dose or different statin
– Less with prava- (maybe rosuva- and pitava-)
– CoQ10, alternate dosing with long-half-life statins
• Drug interactions
– Many (CYP 3A4, 2C9)
– Less with pravastatin
• Recent label changes:
– No more simvastatin 80 mg
– Risk of diabetes, cognitive impairment, less liver monitoring, drug
interactions
Lexi-Comp. NCEP ATP III Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal
of the American College of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Non-Statin Therapy Options
•
•
•
•

Fibrate
Niacin
Bile Acid Sequestrant
Cholesterol absorption
inhibitor
• Omega 3 fatty acid
• PCSK9 Monoclonal
Antibodies (future)

• Complementary and
Alternative Agents
• Cholestoff: Contains plant stanols and
sterols (15 - 20% LDL lowering)
• Fish oil: 2000 - 4000 mg/day
• Soluble fiber: 10 - 25 g/day
• Red Yeast Rice: 1200 - 2400 mg
contains lovastatin 2 - 6 mg
equivalence (20 - 25% LDL lowering)
• CoEnzyme Q10: 100 - 300 mg/day

Patient Education

Health Literacy Sensitive Approaches
• Explain the differences between statins and about medication itself
– Patients also have fear of perceived adverse effects and have
misunderstanding of the benefits
• Use an analogy that the patient can relate to
• Visual aids
• Plain language
• Relate to diabetes and have patient repeat back goals

Lemstra M, Blackburn D, et al. Proportion and risk indicators of nonadherence to
statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574-80.

Motivational Interviewing
• Identify what is important to them (e.g. family, grandkids)
• Involve patient with decision process (shared decision making)
– Mayo Clinic shared decision making tools

Lemstra M, Blackburn D, et al. Proportion and risk indicators of nonadherence to
statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574-80.

Complex Case 1
•

60 YO Male complaining of general pain with past medication history type 2 diabetes,
HTN, dyslipidemia, CAD, MI, CABG, left carotid endarderectomy
Baseline

2 Weeks Later

6 weeks later

Statin

Pravastatin 40mg

None for 4 weeks

None for 10 weeks

CPK (units/L)

None

563

711

LDL (mg/dL)

96

Muscle Pain

Present

Not Resolved

Not resolved

Plan

Stop pravastatin

No drug therapy

?

122

Which of the following is the best recommendation:
A.
B.
C.
D.

Re-challenge statin with rosuvastatin 5mg every other day with coenzyme Q10
supplementation
Re-challenge with pravastatin XXmg
Re-challenge with atorvastatin 40mg
Start bile acid sequestrant

Complex Case 2
•
•
•

•

51 YO Male with past medical history: Dyslipidemia, hypertension, obesity,
hypothyroid, coronary artery disease, type 2 diabetes
Current labs (2015): TC 395, HDL 46, LDL 320, TG 145, AST/ALT 22/38, CK WNL
Medication intolerances: complaints of myalgias with ALL statins (history of hospital
admission in 2013 with AST/ALT 1100/1200, CK 50,000 on atorvastatin 40mg),
gemfibrozil, fenofibrate, niacin, ezetimibe
Not currently on treatment for his dyslipidemia

Which of the following is the best recommendation:
A.
B.
C.
D.

Re-challenge statin with rosuvastatin 5mg every other day with coenzyme Q10
supplementation
Try CholestOff
Try fish oil
Start bile acid sequestrant

The Role and Management of Statins
in Dyslipidemia and Addressing
Patient Barriers to Use

